Life Science

  • With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide TherapyTM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema.

  • Bay City Capital was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed eight venture funds representing over $1.6 billion in capital invested in over 90 companies worldwide. Five of these funds are general life sciences funds, and three are sector funds.

  • DX Biosciences, located in La Jolla, CA. develops novel, non-invasive diagnostic techniques to extract biomarkers from tissue samples.
  • Ellipse Technologies, Inc. is focused on developing innovative technologies for state-of-the-art treatments for a broad spectrum of orthopedic deformity uses including broad spinal applications, orthopedic trauma, limb lengthening and genetic diseases.

  • Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focused on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA).

  • Gobiquity Mobile Health specializes in smartphone apps for the early detection and monitoring of visual disorders to eliminate preventable blindness.

  • Inogen was founded in 2001 to improve quality of life and increase freedom and independence for oxygen therapy users, predominantly Chronic Obstructive Pulmonary Disease (COPD) patients. COPD is the fourth leading cause of death in the United States, and the only major disease with an ever increasing death rate. By 2020 COPD is predicted to become the third leading cause of death worldwide. COPD affects an estimated 30 million people in the US and over 100 million worldwide.

  • Integrated Fluidics’ patented technology enables the development of integrated systems that are expected to be broadly applicable to the performance of biological assays, both in life science research and in clinical diagnostics. Such systems allow investigators to precisely concentrate solutes, separate and move molecules based on electrokinetic properties, and optimize reagent and sample mixing at very low reaction volumes (< 5µL).

  • Interventional Spine®, Inc. was founded in February 2000 to solve a key problem confronting surgeons: how to address the aging population and resulting increase of fractures in patients with osteoporotic bone? Fracture fixation devices available at the time had severe limitations when used in the presence of osteoporotic bone. Interventional Spine product development was grounded on the basis of the Company's Compression (CLASP®) technology, which provides effective fixation in both normal and osteoporotic bone. Due to the superior fracture fixation characteristics of the CLASP® technology, Interventional Spine originally designed devices for the Podiatric and Orthopedic Trauma markets, successfully implanting over 4,000 Orthopedic Trauma Products in patients.

  • InTouch Health provides telehealth services to healthcare organizations to deliver high-quality virtual care, anytime, anywhere.

  • Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.

  • Founded in 1987 as a cutting-edge drug discovery biotech in La Jolla, California, Ligand Pharmaceuticals has built a rich heritage of drug discovery and development innovation. But during those 20 plus years, the pharmaceutical sector has also undergone significant change that has allowed only the most adaptable companies to evolve and thrive. Today, Ligand has done just that and is operating with a business model that is built to generate significant return on investment (ROI) in the increasingly unpredictable and risky biopharma space.

  • MiCardia has developed a new-to-world technology platform to dynamically optimize mitral valve repair, during and after surgery, to achieve the proper shape and size necessary to produce superior clinical outcomes for each patient (implantable devices for heart valve repair). CE Mark for the enCorSQ™ Mitral Valve Repair System™ was received in September, 2011. The first patient to be adjusted was successfully treated in August, 2011, four months after implant.

  • Newport Corporation (Nasdaq: NEWP) is a leading global supplier of advanced technology products and solutions for Scientific Research, Life & Health Science, Aerospace & Defense, Photovoltaics, Industrial Manufacturing, Semiconductors, and Microelectronics markets.

  • Nexus Biosystems (now part of Brooks) is a leading innovator and worldwide provider of enabling technologies, automated sample management solutions and global customer support for pharmaceutical, biotech, biorepository, agrichemical, forensic, and research institutions worldwide.

  • Nexus Dx is a global provider of Near Patient Testing systems and advanced diagnostic solutions. The company is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most.

  • Prolacta Bioscience is a privately held, life sciences company dedicated to improving the quality of life in the most fragile infants through the harmony of nature and science. Prolacta creates specialty formulations made from human milk for the nutritional needs of premature infants in Neonatal Intensive Care Units (NICU). These formulations are sold to NICUs around the country.

  • ReShape Medical® is a medical device manufacturer headquartered in Southern California. The company specializes in a dual-intragastric balloon for weight loss, ReShape Duo®, to be used as an aid in the treatment of obese or overweight patients.

  • Since its foundation in 1890, Santen Pharmaceutical Co., Ltd. has contributed to the protection and improvement of people's eyesight and health. Santen's integrated operations extend from research and development to production and sales of prescription and over-the-counter pharmaceuticals.

  • Sequent Medical, Inc. is a developer of medical devices for the endovascular treatment of neurovascular diseases. The company develops Microbraid technology to create a web aneurysm embolization system for the treatment of both ruptured and unruptured aneurysms.